Gilead Sciences, Inc. (GILD)

You are trying to access subscriber-only content.

If you are a subscriber, log in here.

If you are not a subscriber, click here for your subscription. Subscribers will have unlimited access to our magazine articles and more!

Article Excerpt

Today’s new recommendation comes from Stephen Leeb’s The Complete Investor.

“For more than a decade, drug company Gilead Sciences, Inc. (GILD) has been the leading provider of medicines to combat the HIV virus. While growth in sales of its HIV drugs has slowed, it remains in double digits. Moreover, the company…


You must be logged in to post a comment.